OKYO Pharma
OKYO
8 hedge funds and large institutions have $5.14M invested in OKYO Pharma in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
247% more capital invested
Capital invested by funds: $1.48M → $5.14M (+$3.66M)
60% more funds holding
Funds holding: 5 → 8 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.35% less ownership
Funds ownership: 8.19% → 6.84% (-1.4%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$146K |
| 2 |
Renaissance Technologies
New York
|
+$105K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$39.1K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$387 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$799K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$296 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DIG
1
Dauntless Investment Group
Etna,
New Hampshire
| $4.84M | -$799K | -313,732 | -11% |
|
|
2
Northern Trust
Chicago,
Illinois
| $114K | +$146K | +57,158 | New |
|
|
3
Renaissance Technologies
New York
| $82.4K | +$105K | +41,200 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $30.7K | +$39.1K | +15,355 | New |
|
5
Cerity Partners
New York
| $25.6K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $24.2K | – | – | – |
|
7
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| $20.3K | – | – | – |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| $304 | +$387 | +152 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$296 | -115 | Closed |
|
OKYO Hedge Fund Activity: Q3 2025 in Review
8 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q3 2025, worth a combined $5.14M — up 247% from $1.48M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OKYO positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $146K. The largest seller was Dauntless Investment Group, cutting an estimated $799K.
- 8 institutional investors held OKYO Pharma (OKYO) as of Q3 2025, up from 5 in Q2 2025.
- Funds reported $5.14M of OKYO Pharma stock for Q3 2025, up 247% quarter-over-quarter.
- 4 funds opened new OKYO Pharma positions in Q3 2025 and 1 closed out, a net change of +3 holders.
- The largest OKYO Pharma buyer in Q3 2025 was Northern Trust, an estimated $146K added.
- The largest OKYO Pharma seller in Q3 2025 was Dauntless Investment Group, an estimated $799K sold.
Based on aggregated 13F filings for Q3 2025.